SG10201702979SA - NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS - Google Patents

NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS

Info

Publication number
SG10201702979SA
SG10201702979SA SG10201702979SA SG10201702979SA SG10201702979SA SG 10201702979S A SG10201702979S A SG 10201702979SA SG 10201702979S A SG10201702979S A SG 10201702979SA SG 10201702979S A SG10201702979S A SG 10201702979SA SG 10201702979S A SG10201702979S A SG 10201702979SA
Authority
SG
Singapore
Prior art keywords
novel
peptide dimer
antagonists
dimer antagonists
peptide
Prior art date
Application number
SG10201702979SA
Other languages
English (en)
Inventor
Ashok Bhandari
Dinesh V Patel
Larry C Mattheakis
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of SG10201702979SA publication Critical patent/SG10201702979SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
SG10201702979SA 2012-10-11 2013-10-11 NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS SG10201702979SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261712722P 2012-10-11 2012-10-11
US201361807714P 2013-04-02 2013-04-02
US14/050,349 US9273093B2 (en) 2012-10-11 2013-10-10 α4β7 peptide dimer antagonists

Publications (1)

Publication Number Publication Date
SG10201702979SA true SG10201702979SA (en) 2017-05-30

Family

ID=50477907

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502812WA SG11201502812WA (en) 2012-10-11 2013-10-11 NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS
SG10201702979SA SG10201702979SA (en) 2012-10-11 2013-10-11 NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201502812WA SG11201502812WA (en) 2012-10-11 2013-10-11 NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS

Country Status (13)

Country Link
US (3) US9273093B2 (h)
EP (1) EP2906584B1 (h)
JP (2) JP6480865B2 (h)
KR (1) KR20150084808A (h)
CN (1) CN105102470A (h)
AU (2) AU2013329135B2 (h)
CA (1) CA2888479A1 (h)
HK (1) HK1213583A1 (h)
IL (1) IL238123A0 (h)
IN (1) IN2015DN03039A (h)
NZ (1) NZ706909A (h)
SG (2) SG11201502812WA (h)
WO (1) WO2014059213A1 (h)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
WO2014153002A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
US9822157B2 (en) 2013-03-15 2017-11-21 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294901A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
PL3143037T3 (pl) 2014-05-16 2022-01-31 Protagonist Therapeutics, Inc. Peptydy tioeterowe - antagoniści integryny alfa-4-beta-7
EP3169403B9 (en) 2014-07-17 2024-07-03 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3201217A4 (en) * 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
AU2015328002A1 (en) * 2014-10-01 2017-04-27 Protagonist Therapeutics, Inc. Novel alpha4beta7 peptide monomer and dimer antagonists
EP3310376A4 (en) * 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017041001A2 (en) 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
KR20180100302A (ko) 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
US11046695B2 (en) * 2015-11-11 2021-06-29 Zealand Pharma A/S Fragment synthesis of substituted cyclic peptides
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3013463C (en) 2016-02-04 2024-05-21 The California Institute For Biomedical Research Humanized anti-cd3 antibodies, conjugates and uses thereof
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
JP7035044B2 (ja) 2016-11-11 2022-03-14 ジーランド ファーマ エー／エス α４β７インテグリンを標的とする環状ペプチド多量体
MX2019013362A (es) 2017-05-10 2020-08-17 Zealand Pharma As PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA.
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2020244884A1 (en) * 2019-03-28 2021-11-18 Protagonist Therapeutics, Inc. Methods for synthesizing β-homoamino acids
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
AU2021205415A1 (en) * 2020-01-10 2022-07-21 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists
JP2023511551A (ja) 2020-01-15 2023-03-20 ヤンセン バイオテツク，インコーポレーテツド インターロイキン２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CN118027153A (zh) 2020-01-15 2024-05-14 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
MX2023005994A (es) 2020-11-20 2023-08-11 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23.
WO2022257979A1 (en) 2021-06-09 2022-12-15 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) * 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH06509551A (ja) * 1991-04-05 1994-10-27 ジェネンテク，インコーポレイテッド Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
AU8399998A (en) * 1997-07-11 1999-02-08 Innerdyne, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
US6271252B1 (en) 1997-11-24 2001-08-07 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
JP2002524108A (ja) * 1998-07-28 2002-08-06 インナーダイン， インコーポレイテッド 吸収性近接照射療法および化学療法送達デバイスならびに方法
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
NZ514602A (en) 1999-04-12 2003-06-30 Aventis Pharma Ltd Substituted bicyclic heteroaryl compounds as integrin antagonists
AU2001262089A1 (en) 2000-03-14 2001-09-24 Novartis Ag Alpha4beta1 and alpha4beta7 integrin inhibitors
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
WO2004058307A1 (en) 2002-12-18 2004-07-15 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
CA2544223C (en) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1695255B1 (en) 2003-12-19 2016-09-07 Applied Biosystems, LLC Methods and systems for protein and peptide evidence assembly
PL2177537T3 (pl) 2004-01-09 2012-06-29 Pfizer Przeciwciała przeciw MadCAM
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
EP1781689A4 (en) 2004-06-24 2010-11-10 Inst Medical W & E Hall CONJUGATES AND THEIR THERAPEUTIC APPLICATIONS
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006058539A2 (en) 2004-11-30 2006-06-08 Gastrotech Pharma A/S Growth hormone secretagogue receptor 1a ligands
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2465223T3 (es) 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
US20090131317A1 (en) * 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
JP2011501941A (ja) 2007-07-06 2011-01-20 バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ Ｉｌ−２３レセプターのアンタゴニストおよびその使用
WO2009039185A1 (en) * 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
WO2009045536A2 (en) 2007-10-05 2009-04-09 The University Of North Carolina At Chapel Hill Receptor targeted oligonucleotides
DE102009007381A1 (de) * 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
WO2010116752A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 ニューロメジンｕ誘導体
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN104011066A (zh) 2011-12-09 2014-08-27 加利福尼亚大学董事会 经修饰的微型铁调素肽及其使用方法
WO2013177432A1 (en) 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
CA2901436A1 (en) 2013-02-15 2014-08-21 Srx Cardio, Llc Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to modulate serum low density lipoprotein (ldl) levels
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
MX366341B (es) 2013-06-24 2019-07-05 Canbas Co Ltd Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.

Also Published As

Publication number Publication date
KR20150084808A (ko) 2015-07-22
AU2018201599A1 (en) 2018-03-29
JP2019001825A (ja) 2019-01-10
NZ706909A (en) 2018-11-30
HK1213583A1 (zh) 2016-07-08
JP6480865B2 (ja) 2019-03-13
AU2013329135A1 (en) 2015-04-30
JP2015533833A (ja) 2015-11-26
US20140193465A1 (en) 2014-07-10
CN105102470A (zh) 2015-11-25
WO2014059213A1 (en) 2014-04-17
US9273093B2 (en) 2016-03-01
AU2013329135B2 (en) 2018-02-01
EP2906584A1 (en) 2015-08-19
US20190248870A1 (en) 2019-08-15
US20160368966A1 (en) 2016-12-22
EP2906584B1 (en) 2019-11-20
IL238123A0 (en) 2015-05-31
EP2906584A4 (en) 2016-06-15
IN2015DN03039A (h) 2015-10-02
CA2888479A1 (en) 2014-04-17
SG11201502812WA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
SG10201702979SA (en) NOVEL α4β7 PEPTIDE DIMER ANTAGONISTS
IL291571A (en) cx3cr1 binding polypeptides
SG10201708103RA (en) Novel α4β7 Peptide Dimer Antagonists
IL229387A0 (en) Antagonists to spiro-oxindole mdm2
IL238974A0 (en) cxcr7 antagonists
ZA201408880B (en) Polypeptides having transgalactosylating activity
ZA201306005B (en) Novel sulfonaminoquinoline hepcidin antagonists
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
GB201220474D0 (en) Polypeptides
LT2793883T (lt) Trpm8 antagonistai
HUP1300139A2 (en) Phenoxypiperidine h3 antagonists
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
BR112015005750A2 (pt) antagonistas peptídicos do receptor de vasopressina-2
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
IL235840A0 (en) Alternaria peptides
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
HRP20160867T1 (hr) ANTAGONISTI mGLU2/3
AU346944S (en) Skirt
AU346087S (en) skirt
AU344779S (en) Skirt
GB201221414D0 (en) Trans-locating peptide
GB201200624D0 (en) Peptide
GB201200623D0 (en) Peptide